Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Los efectos secundarios generalmente no son muy graves, pero pueden ser lo suficientemente molestos como para requerir una fase de dosificacin durante las etapas iniciales del tratamiento
The price remains flat across all dose levelsyour dose may need to go up, but your price won't
All handling must comply with applicable laboratory procedures, institutional protocols, and qualified research standards
Your body should be adapting to the medication, not fighting it harder each day
its celebrated tendon, ligament, and muscle results are entirely rodent and cell-culture work
US$ 23.84
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
US$ 29.69
US$ 22.56
US$ 28.55
